JP2015527321A - アルカリ化剤を含まないラキニモド製剤 - Google Patents

アルカリ化剤を含まないラキニモド製剤 Download PDF

Info

Publication number
JP2015527321A
JP2015527321A JP2015521771A JP2015521771A JP2015527321A JP 2015527321 A JP2015527321 A JP 2015527321A JP 2015521771 A JP2015521771 A JP 2015521771A JP 2015521771 A JP2015521771 A JP 2015521771A JP 2015527321 A JP2015527321 A JP 2015527321A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
stable pharmaceutical
laquinimod
composition according
filler
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015521771A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015527321A5 (https=
Inventor
サルファティ、ガディ
ロビンガー、イオアナ
リヒト、ダニト
サファディ、ムハンマド
Original Assignee
テバ ファーマシューティカル インダストリーズ リミティド
テバ ファーマシューティカル インダストリーズ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テバ ファーマシューティカル インダストリーズ リミティド, テバ ファーマシューティカル インダストリーズ リミティド filed Critical テバ ファーマシューティカル インダストリーズ リミティド
Publication of JP2015527321A publication Critical patent/JP2015527321A/ja
Publication of JP2015527321A5 publication Critical patent/JP2015527321A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015521771A 2012-07-11 2013-07-10 アルカリ化剤を含まないラキニモド製剤 Pending JP2015527321A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261670268P 2012-07-11 2012-07-11
US61/670,268 2012-07-11
PCT/US2013/049894 WO2014011750A1 (en) 2012-07-11 2013-07-10 Laquinimod formulations without alkalizing agent

Publications (2)

Publication Number Publication Date
JP2015527321A true JP2015527321A (ja) 2015-09-17
JP2015527321A5 JP2015527321A5 (https=) 2016-09-01

Family

ID=49914501

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015521771A Pending JP2015527321A (ja) 2012-07-11 2013-07-10 アルカリ化剤を含まないラキニモド製剤

Country Status (19)

Country Link
US (1) US20140018386A1 (https=)
EP (1) EP2872141A4 (https=)
JP (1) JP2015527321A (https=)
KR (1) KR20150036553A (https=)
CN (1) CN104470519A (https=)
AR (1) AR091706A1 (https=)
AU (1) AU2013290274A1 (https=)
BR (1) BR112015000321A2 (https=)
CA (1) CA2873230A1 (https=)
EA (1) EA201590193A1 (https=)
HK (1) HK1209054A1 (https=)
IL (1) IL236229A0 (https=)
MX (1) MX2015000398A (https=)
NZ (1) NZ630241A (https=)
SG (2) SG10201700198VA (https=)
TW (1) TW201408299A (https=)
UA (1) UA115555C2 (https=)
WO (1) WO2014011750A1 (https=)
ZA (1) ZA201500287B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2445451T3 (es) 2007-12-20 2014-03-03 Teva Pharmaceutical Industries, Ltd. Preparaciones estables de laquinimod
CN106063787A (zh) 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
JP2015535287A (ja) 2012-11-07 2015-12-10 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドのアミン塩
NZ630427A (en) 2013-03-14 2017-06-30 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof
EA201692180A1 (ru) 2014-04-29 2017-08-31 Тева Фармасьютикал Индастриз Лтд. Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации
CN107823168A (zh) * 2017-10-25 2018-03-23 北京素维生物科技有限公司 一种快速溶解的片剂及其制备方法
CN107823150A (zh) * 2017-10-25 2018-03-23 北京素维生物科技有限公司 一种可快速分散的片剂及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007182452A (ja) * 2000-01-26 2007-07-19 Astrazeneca Ab 医薬組成物
US20090162432A1 (en) * 2007-12-20 2009-06-25 Muhammad Safadi Stable laquinimod preparations
US7589208B2 (en) * 2004-02-06 2009-09-15 Active Biotech Ab Compositions containing quinoline compounds
JP2009539984A (ja) * 2006-06-12 2009-11-19 テバ ファーマシューティカル インダストリーズ リミティド 安定性ラキニモド製剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7884208B2 (en) * 2005-10-19 2011-02-08 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium, and process for the manufacture thereof
WO2010070449A2 (en) * 2008-12-17 2010-06-24 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
WO2013016686A1 (en) * 2011-07-28 2013-01-31 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and interferon-beta

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007182452A (ja) * 2000-01-26 2007-07-19 Astrazeneca Ab 医薬組成物
US7589208B2 (en) * 2004-02-06 2009-09-15 Active Biotech Ab Compositions containing quinoline compounds
JP2009539984A (ja) * 2006-06-12 2009-11-19 テバ ファーマシューティカル インダストリーズ リミティド 安定性ラキニモド製剤
US20090162432A1 (en) * 2007-12-20 2009-06-25 Muhammad Safadi Stable laquinimod preparations

Also Published As

Publication number Publication date
NZ630241A (en) 2017-09-29
ZA201500287B (en) 2016-10-26
EA201590193A1 (ru) 2015-04-30
TW201408299A (zh) 2014-03-01
IL236229A0 (en) 2015-01-29
US20140018386A1 (en) 2014-01-16
EP2872141A4 (en) 2016-01-13
BR112015000321A2 (pt) 2017-06-27
SG11201407688QA (en) 2014-12-30
WO2014011750A1 (en) 2014-01-16
EP2872141A1 (en) 2015-05-20
HK1209054A1 (zh) 2016-03-24
AR091706A1 (es) 2015-02-25
WO2014011750A8 (en) 2014-12-04
MX2015000398A (es) 2015-04-10
SG10201700198VA (en) 2017-02-27
AU2013290274A1 (en) 2014-11-27
KR20150036553A (ko) 2015-04-07
UA115555C2 (uk) 2017-11-27
CN104470519A (zh) 2015-03-25
CA2873230A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
JP2015527321A (ja) アルカリ化剤を含まないラキニモド製剤
CN104173272B (zh) 一种异硫氰酸酯类化合物的缓释制剂
US20230285386A1 (en) IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
CN101951889A (zh) 伊马替尼组合物
EP2514422B1 (en) Elution stabilized teneligliptin preparation
ES2732711T3 (es) Composición farmacéutica estable sólida de citisina y proceso para la preparación de la misma
EP4221704B1 (en) Pharmaceutical formulations for treating diseases mediated by kdm1a
EP2540317A1 (en) Sustained-release solid preparation for oral use
CA2869882C (en) Capsule formulation
US20160008328A1 (en) Stable Pharmaceutical Package Comprising Azilsartan Medoxomil
CA3181646A1 (en) Oral formulation comprising a crystalline form of rabeximod
JPWO2015199115A1 (ja) 経口投与用医薬組成物
WO2007049626A1 (ja) カベルゴリン含有経口固形製剤
KR20240093577A (ko) 약학적 조성물
WO2023062647A1 (en) Pomalidomide formulation
EP3065700A1 (en) Orodispersible pharmaceutical compositions comprising aripiprazole
KR20010075385A (ko) (2ｓ,3ｓ,5ｒ)-2-(3,5-디플루오로페닐)-3,5-디메틸-2-모르폴린올 및 안정화 유효량의 알긴산을 포함하는 경구 투여 제제
HK1206989B (en) Encapsulated formulation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160711

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170609

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171003

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180306